PD
CCCC icon

Point72 (DIFC)’s C4 Therapeutics CCCC Stock Holding History

Point72 (DIFC)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$519 Sell
234
-3,719
-94% -$8.93K ﹤0.01% 1086
2025
Q2 		$5.65K Buy
+3,953
New +$5.75K ﹤0.01% 1368
2025
Q1 		– Sell
-11,333
Closed -$40.8K – 1703
2024
Q4 		$40.8K Buy
11,333
+2,460
+28% +$12.2K ﹤0.01% 1154
2024
Q3 		$50.6K Buy
+8,873
New +$53.4K ﹤0.01% 1088

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 (DIFC)'s CCCC Position: Q3 2025 in Review

Point72 (DIFC) reduced its C4 Therapeutics (CCCC) stake by 94% in Q3 2025, selling an estimated $8.93K and leaving 234 shares worth $519. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

Point72 (DIFC) first reported a position in CCCC in Q3 2024 and has held it in 4 quarters since. The position peaked at $50.6K in Q3 2024. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • Point72 (DIFC) held 234 shares of C4 Therapeutics worth $519 as of Q3 2025.
  • Point72 (DIFC) sold 3,719 C4 Therapeutics shares in Q3 2025, an estimated $8.93K.
  • C4 Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1086 holding.
  • Point72 (DIFC) first reported a position in C4 Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Point72 (DIFC)'s C4 Therapeutics position peaked at $50.6K in Q3 2024.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.